INS and Hyperglycemia: The mainstay insulin replacement therapy does not parallel normal insulin kinetics and fails to restore normoglycemia in most T1D patients, who experience an increased risk of hypoglycemia, failure to control postprandial hyperglycemia and unpredictable diurnal glucose fluctuations [1].